[HTML][HTML] Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

L Zhong, Y Li, L Xiong, W Wang, M Wu… - Signal transduction and …, 2021 - nature.com
Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Targeting apoptosis in cancer therapy

BA Carneiro, WS El-Deiry - Nature reviews Clinical oncology, 2020 - nature.com
For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

Apoptosis deregulation and the development of cancer multi-drug resistance

CM Neophytou, IP Trougakos, N Erin, P Papageorgis - Cancers, 2021 - mdpi.com
Simple Summary Despite recent therapeutic advances against cancer, many patients do not
respond well or respond poorly, to treatment and develop resistance to more than one anti …

Apoptosis and apoptotic body: disease message and therapeutic target potentials

X Xu, Y Lai, ZC Hua - Bioscience reports, 2019 - portlandpress.com
Apoptosis is widely known as programmed cell death eliciting no inflammatory responses.
The intricacy of apoptosis has been a focus of an array of researches, accumulating a wealth …

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang… - Nature medicine, 2019 - nature.com
B-cell lymphoma extra large (BCL-XL) is a well-validated cancer target. However, the on-
target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as …

[HTML][HTML] Understanding apoptosis and apoptotic pathways targeted cancer therapeutics

R Jan - Advanced pharmaceutical bulletin, 2019 - ncbi.nlm.nih.gov
Various physiological processes involve appropriate tissue developmental process and
homeostasis-the pathogenesis of several diseases connected with deregulatory apoptosis …

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity

D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang… - Nature …, 2021 - nature.com
Abstract PROteolysis-TArgeting Chimeras (PROTACs) have emerged as an innovative drug
development platform. However, most PROTACs have been generated empirically because …

[HTML][HTML] The role of NF-κB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy

E Pavitra, J Kancharla, VK Gupta, K Prasad… - Biomedicine & …, 2023 - Elsevier
Breast cancer (BC) is the second most fatal disease and is the prime cause of cancer allied
female deaths. BC is caused by aberrant tumor suppressor genes and oncogenes regulated …

Acute spinal cord injury: Pathophysiology and pharmacological intervention

Y Zhang, A Al Mamun, Y Yuan… - Molecular …, 2021 - spandidos-publications.com
Spinal cord injury (SCI) is one of the most debilitating of all the traumatic conditions that
afflict individuals. For a number of years, extensive studies have been conducted to clarify …

Artemisinins: pharmacological actions beyond anti-malarial

WE Ho, HY Peh, TK Chan, WSF Wong - Pharmacology & therapeutics, 2014 - Elsevier
Artemisinins are a family of sesquiterpene trioxane lactone anti-malarial agents originally
derived from Artemisia annua L. The anti-malarial action of artemisinins involves the …